NCT02825914View on ClinicalTrials.gov

CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

July 1, 2019

Study Completion Date

October 1, 2019

Conditions
Colitis, UlcerativeInflammatory Bowel Diseases
Interventions
DIETARY_SUPPLEMENT

Casein glycomacropeptide (CGMP)

DIETARY_SUPPLEMENT

Placebo

Trial Locations (1)

8000

Department of medicine V (Hepatology and Gastroenterology), Aarhus C

All Listed Sponsors
lead

University of Aarhus

OTHER

NCT02825914 - CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM) | Biotech Hunter | Biotech Hunter